BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 32727455)

  • 21. The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD: current evidence and future prospects.
    Derom E; Brusselle GG; Joos GF
    Ther Adv Respir Dis; 2019; 13():1753466619843426. PubMed ID: 31002020
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients.
    van Noord JA; Cornelissen PJ; Aumann JL; Platz J; Mueller A; Fogarty C
    Respir Med; 2009 Jan; 103(1):22-9. PubMed ID: 19022642
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis.
    Ismaila AS; Huisman EL; Punekar YS; Karabis A
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2495-517. PubMed ID: 26604738
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial.
    Vestbo J; Papi A; Corradi M; Blazhko V; Montagna I; Francisco C; Cohuet G; Vezzoli S; Scuri M; Singh D
    Lancet; 2017 May; 389(10082):1919-1929. PubMed ID: 28385353
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease.
    Cazzola M; Rogliani P; Ora J; Matera MG
    Expert Rev Clin Pharmacol; 2015; 8(5):529-39. PubMed ID: 26294073
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lung deposition of inhaled once-daily long-acting muscarinic antagonists
    Crater GD; Johnson K; Ward J; Backer J
    Ther Adv Respir Dis; 2022; 16():17534666221077561. PubMed ID: 35234085
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review.
    Ulrik CS
    Int J Chron Obstruct Pulmon Dis; 2014; 9():331-8. PubMed ID: 24729699
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Questionnaire on switching from the tiotropium HandiHaler to the Respimat inhaler in patients with chronic obstructive pulmonary disease: changes in handling and preferences immediately and several years after the switch.
    Hanada S; Wada S; Ohno T; Sawaguchi H; Muraki M; Tohda Y
    Int J Chron Obstruct Pulmon Dis; 2015; 10():69-77. PubMed ID: 25609941
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized, Double-Blind, Dose-Finding Study for Tiotropium when Added to Olodaterol, Administered via the Respimat® Inhaler in Patients with Chronic Obstructive Pulmonary Disease.
    Aalbers R; Maleki-Yazdi MR; Hamilton A; Waitere-Wijker S; Zhao Y; Amatto VC; Schmidt O; Bjermer L
    Adv Ther; 2015 Sep; 32(9):809-22. PubMed ID: 26404912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat® Soft Mist™ Inhaler in COPD.
    Hodder R; Pavia D; Lee A; Bateman E
    Int J Chron Obstruct Pulmon Dis; 2011; 6():245-51. PubMed ID: 21814460
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tiotropium bromide inhalation powder: a review of its use in the management of chronic obstructive pulmonary disease.
    Keating GM
    Drugs; 2012 Jan; 72(2):273-300. PubMed ID: 22217233
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-life effectiveness of indacaterol-glycopyrronium after switching from tiotropium or salmeterol/fluticasone therapy in patients with symptomatic COPD: the POWER study.
    Kaplan A; Chapman KR; Anees SM; Mayers I; Rochdi D; Djandji M; Préfontaine D; McIvor A
    Int J Chron Obstruct Pulmon Dis; 2019; 14():249-260. PubMed ID: 30718952
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD.
    Buhl R; Banerji D
    Int J Chron Obstruct Pulmon Dis; 2012; 7():729-41. PubMed ID: 23118536
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tiotropium/Olodaterol: A Review in COPD.
    Dhillon S
    Drugs; 2016 Jan; 76(1):135-46. PubMed ID: 26683033
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tiotropium bromide, a new, once-daily inhaled anticholinergic bronchodilator for chronic-obstructive pulmonary disease.
    ZuWallack AR; ZuWallack RL
    Expert Opin Pharmacother; 2004 Aug; 5(8):1827-35. PubMed ID: 15264997
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tiotropium/Olodaterol: A Review in COPD.
    Blair HA
    Drugs; 2019 Jun; 79(9):997-1008. PubMed ID: 31119643
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.
    Farne HA; Cates CJ
    Cochrane Database Syst Rev; 2015 Oct; (10):CD008989. PubMed ID: 26490945
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of switching tiotropium HandiHaler® to Respimat® Soft Mist™ Inhaler in patients with COPD: the difference of adverse events and usability between inhaler devices.
    Asakura Y; Nishimura N; Maezawa K; Terajima T; Kizu J; Chohnabayashi N
    J Aerosol Med Pulm Drug Deliv; 2013 Feb; 26(1):41-5. PubMed ID: 22691112
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tiotropium administered by a pressurized metered dose inhaler (pMDI) and spacer produces a similar bronchodilator response as that administered by a Rotahaler in adult subjects with stable moderate-to-severe COPD.
    Brashier B; Dhembare P; Jantikar A; Mahadik P; Gokhale P; Gogtay JA; Salvi SS
    Respir Med; 2007 Dec; 101(12):2464-71. PubMed ID: 17719763
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tiotropium/Olodaterol Delays Clinically Important Deterioration Compared with Tiotropium Monotherapy in Patients with Early COPD: a Post Hoc Analysis of the TONADO
    Rabe KF; Chalmers JD; Miravitlles M; Kocks JWH; Tsiligianni I; de la Hoz A; Xue W; Singh D; Ferguson GT; Wedzicha J
    Adv Ther; 2021 Jan; 38(1):579-593. PubMed ID: 33175291
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.